Literature DB >> 12774925

Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders.

Toshie Ogasawara1, Masako Yasuyama, Kiyotaka Kawauchi.   

Abstract

Signaling molecules such as p21(ras) (Ras), mitogen-activated protein kinase (MAPK), and Akt kinase play pivotal roles in the proliferation and survival of lymphoid cells in response to many kinds of stimulation. It is not fully understood, however, how these molecules participate in the growth of malignant lymphoid cells. We determined whether Ras, MAPKs such as extracellular signal-regulated kinase (ERK), c-Jun amino-terminal kinase (JNK), and p38 MAPK, and Akt kinase are activated in B-cell tumors, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, Burkitt-like lymphoma, diffuse large B-cell lymphoma, and plasma cell leukemia. We found that Lyn protein tyrosine kinase was constitutively phosphorylated on tyrosine, and that ERK and p38 MAPK were constitutively active in all cases of the B-cell tumor. In contrast, activation of Ras and Akt kinase was found in limited cases, and JNK kinase activity was not observed in any case. These results suggest that ERK and p38 play roles in the oncogenesis of B-cell tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12774925     DOI: 10.1007/bf02982645

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  18 in total

Review 1.  Mammalian MAP kinase signalling cascades.

Authors:  L Chang; M Karin
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

2.  p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr.

Authors:  Malgorzata Korus; Gwendolyn M Mahon; Li Cheng; Ian P Whitehead
Journal:  Oncogene       Date:  2002-07-11       Impact factor: 9.867

3.  Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line.

Authors:  S P Srinivasa; P D Doshi
Journal:  Leukemia       Date:  2002-02       Impact factor: 11.528

4.  JNK and p38 are activated by erythropoietin (EPO) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD57 cells.

Authors:  S M Jacobs-Helber; J J Ryan; S T Sawyer
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

5.  Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1.

Authors:  Juan A Recio; Glenn Merlino
Journal:  Oncogene       Date:  2002-02-07       Impact factor: 9.867

6.  Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase.

Authors:  A M Whalen; S C Galasinski; P S Shapiro; T S Nahreini; N G Ahn
Journal:  Mol Cell Biol       Date:  1997-04       Impact factor: 4.272

7.  Phosphatidylinositol 3-kinase and NF-kappa B/Rel are at the divergence of CD40-mediated proliferation and survival pathways.

Authors:  S Andjelic; C Hsia; H Suzuki; T Kadowaki; S Koyasu; H C Liou
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

8.  Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors.

Authors:  R Hoshino; Y Chatani; T Yamori; T Tsuruo; H Oka; O Yoshida; Y Shimada; S Ari-i; H Wada; J Fujimoto; M Kohno
Journal:  Oncogene       Date:  1999-01-21       Impact factor: 9.867

9.  Activation of extracellular signal-regulated kinase through B-cell antigen receptor in B-cell chronic lymphocytic leukemia.

Authors:  Kiyotaka Kawauchi; Toshie Ogasawara; Masako Yasuyama
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

Review 10.  Tyrosine kinase SYK: essential functions for immunoreceptor signalling.

Authors:  M Turner; E Schweighoffer; F Colucci; J P Di Santo; V L Tybulewicz
Journal:  Immunol Today       Date:  2000-03
View more
  11 in total

1.  Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma.

Authors:  Penny Anders; Prasanna M Bhende; Michael Foote; Dirk P Dittmer; Steven I Park; Blossom Damania
Journal:  Leuk Lymphoma       Date:  2014-06-06

2.  The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.

Authors:  Savita Bhalla; Andrew M Evens; Bojie Dai; Sheila Prachand; Leo I Gordon; Ronald B Gartenhaus
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

Review 3.  Combination of celecoxib (Celebrex®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.

Authors:  Tam Nm Dinh; Alexandra S Onea; Ali R Jazirehi
Journal:  Am J Clin Exp Immunol       Date:  2017-05-15

4.  P38 mitogen activated protein kinase expression and regulation by interleukin-4 in human B cell non-Hodgkin lymphomas.

Authors:  Hu Ding; Ali M Gabali; Stephen D Jenson; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Hematop       Date:  2009-10-21       Impact factor: 0.196

5.  Transcription factors down-stream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus.

Authors:  Tuba Esfandyari; Ayalew Tefferi; Anna Szmidt; Tommy Alain; Pawel Zwolak; Terra Lasho; Patrick W Lee; Faris Farassati
Journal:  Mol Oncol       Date:  2009-07-28       Impact factor: 6.603

6.  Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells.

Authors:  Andrei V Ougolkov; Nancy D Bone; Martin E Fernandez-Zapico; Neil E Kay; Daniel D Billadeau
Journal:  Blood       Date:  2007-04-26       Impact factor: 22.113

7.  Hyperplastic Growth of Pulmonary Artery Smooth Muscle Cells from Subjects with Pulmonary Arterial Hypertension Is Activated through JNK and p38 MAPK.

Authors:  Jamie L Wilson; Jun Yu; Linda Taylor; Peter Polgar
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

8.  P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.

Authors:  Gabriel G Vega; Alejandro Avilés-Salas; J Ramón Chalapud; Melisa Martinez-Paniagua; Rosana Pelayo; Héctor Mayani; Rogelio Hernandez-Pando; Otoniel Martinez-Maza; Sara Huerta-Yepez; Benjamin Bonavida; Mario I Vega
Journal:  BMC Cancer       Date:  2015-10-16       Impact factor: 4.430

9.  A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404).

Authors:  Daniel R Greenwald; Hailun Li; Selina M Luger; Ronald S Go; David King; Taral Patel; Randy D Gascoyne; Jill Kolesar; Brad S Kahl; Sandra Horning
Journal:  J Hematol Oncol       Date:  2013-07-05       Impact factor: 17.388

10.  Capsaicin Induces Apoptosis in KSHV-Positive Primary Effusion Lymphoma by Suppressing ERK and p38 MAPK Signaling and IL-6 Expression.

Authors:  Misato Moriguchi; Tadashi Watanabe; Ayano Kadota; Masahiro Fujimuro
Journal:  Front Oncol       Date:  2019-02-19       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.